INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132901, 'Trimipramine', 'Losartan', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133058/', '', 'Sacubitril, Aliskiren', 'St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Escitalopram', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132902, 'Valdecoxib', 'Losartan', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Concomitant use of NSAIDs and angiotensin II receptor antagonists may cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function.', 'DDInter', 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133059/', '', 'Chondroitin sulfate, Esomeprazole, Glucosamine', 'Sacubitril, Nebivolol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132903, 'Zaleplon', 'Losartan', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133060/', '', 'Sacubitril, Aliskiren', 'Suvorexant, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Methohexital, Lemborexant, Estazolam, Ethchlorvynol, Tasimelteon, Melatonin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132904, 'Ziprasidone', 'Losartan', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', 'DDInter', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133061/', '', 'Droperidol, Pimozide, Pimavanserin', 'Sacubitril, Aliskiren', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132905, 'Zolpidem', 'Losartan', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133062/', '', 'Suvorexant, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Methohexital, Lemborexant, Estazolam, Ethchlorvynol, Tasimelteon, Melatonin, More', 'Sacubitril', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132906, 'Amprenavir', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133063/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132907, 'Boceprevir', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133064/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132908, 'Fedratinib', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133065/', '', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132909, 'Flurbiprofen (ophthalmic)', 'Loteprednol (ophthalmic)', 'Moderate', 'Concomitant use of ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) and ophthalmic steroids may increase the potential for healing problems, as both can slow or delay healing.', 'DDInter', 'The use of ophthalmic NSAIDs in combination with ophthalmic corticosteroids should be avoided unless benefits outweigh the potential risks.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133066/', '', 'Rabeprazole, Phenylbutazone, Indomethacin, Tolazoline, Ketoprofen, Diclofenac, Piroxicam, Flurbiprofen, Naproxen, Ibuprofen, Tolmetin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132910, 'Fosamprenavir', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133067/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132911, 'Idelalisib', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133068/', '', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132912, 'Indinavir', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133069/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132913, 'Loteprednol (ophthalmic)', 'Lonafarnib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133070/', '', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132914, 'Miconazole', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133071/', '', 'Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132915, 'Nefazodone', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133072/', '', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132916, 'Nelfinavir', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133073/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132917, 'Nepafenac (ophthalmic)', 'Loteprednol (ophthalmic)', 'Moderate', 'Concomitant use of ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) and ophthalmic steroids may increase the potential for healing problems, as both can slow or delay healing.', 'DDInter', 'The use of ophthalmic NSAIDs in combination with ophthalmic corticosteroids should be avoided unless benefits outweigh the potential risks.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133074/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132918, 'Posaconazole', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133075/', '', 'Fluconazole, Caspofungin, Amphotericin B, Micafungin, Oteseconazole, Flucytosine, Anidulafungin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132919, 'Smallpox (Vaccinia) Vaccine, Live', 'Loteprednol (ophthalmic)', 'Major', 'The administration of live virus smallpox vaccine during corticosteroid therapy may be associated with a risk of localized or disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients receiving high dosages of systemic corticosteroids and those who are systemically immunosuppressed due to long-term topical or aerosol use of corticosteroids may also have an increased risk of neurologic reactions to vaccines and decreased or suboptimal immunologic response due to antibody inhibition. The risk of ocular complications may be increased in patients who are using ophthalmic corticosteroids.', 'DDInter', 'Routine nonemergency smallpox vaccination is considered a relative contraindication in patients receiving immunosuppressive corticosteroid therapy or ophthalmic corticosteroids. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored. The interval depends on the dosage, duration, and route of corticosteroid therapy administered, but may be at least 3 months in most cases of systemic corticosteroid use. In patients who have recently been vaccinated, high-dose corticosteroid therapy should not be initiated for at least 2 weeks. Household contacts of immunosuppressed patients should also not be vaccinated. However, there are no absolute contraindications to vaccination if a high-risk exposure has occurred. In an outbreak emergency, smallpox vaccine is generally recommended for all persons, regardless of medical conditions. The risk for experiencing serious complications from the vaccine should be weighed against the risk of acquiring a potentially fatal smallpox infection. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Routine nonemergency smallpox vaccination is considered a relative contraindication in patients receiving immunosuppressive corticosteroid therapy or ophthalmic corticosteroids.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133076/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132920, 'Suprofen (ophthalmic)', 'Loteprednol (ophthalmic)', 'Moderate', 'Concomitant use of ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) and ophthalmic steroids may increase the potential for healing problems, as both can slow or delay healing.', 'DDInter', 'The use of ophthalmic NSAIDs in combination with ophthalmic corticosteroids should be avoided unless benefits outweigh the potential risks.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133077/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132921, 'Telaprevir', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133078/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132922, 'Telithromycin', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133079/', '', 'Dirithromycin, Lincomycin, Azithromycin, Clindamycin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132923, 'Troleandomycin', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133080/', '', 'Dirithromycin, Lincomycin, Azithromycin, Clindamycin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132924, 'Tucatinib', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133081/', '', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132925, 'Voriconazole', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133082/', '', 'Fluconazole, Caspofungin, Amphotericin B, Micafungin, Oteseconazole, Flucytosine, Anidulafungin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132926, 'Voxelotor', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', 'DDInter', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133083/', '', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132927, 'Amprenavir', 'Lovastatin', 'Major', 'Protease inhibitors (PIs) may significantly increase the plasma concentrations of certain HMG-CoA reductase inhibitors. The mechanism is PI inhibition of CYP450 3A4 metabolism.High levels of HMG-CoA reductase inhibitory activity in plasma are associated with an increased risk of musculoskeletal toxicity, including myopathy and rhabdomyolysis, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.', 'DDInter', 'Simvastatin or lovastatin are considered contraindicated in patients treated with fosamprenavir due to the potential for severe interaction. Red yeast rice (which contains lovastatin) should also be avoided in patients treated with PIs. Fluvastatin and pravastatin are probably safer alternatives, since they are not metabolized by CYP450 3A4. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Simvastatin or lovastatin are considered contraindicated in patients treated with fosamprenavir due to the potential for severe interaction.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133084/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132928, 'Anisindione', 'Lovastatin', 'Moderate', 'Lovastatin may enhance the hypoprothrombinemic effects of warfarin. Clinically significant alterations in anticoagulation have been reported. The mechanism is unknown.', 'DDInter', 'Caution is recommended if any HMG-CoA reductase inhibitor is used concomitantly with any oral anticoagulant. Close clinical and laboratory monitoring for altered anticoagulant effect is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is recommended if any HMG-CoA reductase inhibitor is used concomitantly with any oral anticoagulant.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133085/', '', 'Mipomersen, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cerivastatin, Lomitapide, Niacin, Bempedoic acid, Alirocumab, Amlodipine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132929, 'Aurothioglucose', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133086/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Cerivastatin, More', 'Penicillamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132930, 'Bedaquiline', 'Lovastatin', 'Moderate', 'Coadministration of bedaquiline with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'DDInter', 'The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; other antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; ketolide and macrolide antibiotics; interferons; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), especially in patients with diminished hepatic reserve. Patients treated with bedaquiline should have serum ALT, AST, alkaline phosphatase, and bilirubin monitored at baseline and monthly during treatment, or as often as needed. An increase of serum aminotransferases to greater than 3 times ULN should be followed by repeat testing within 48 hours. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Discontinue bedaquiline if aminotransferase elevations are accompanied by total bilirubin elevation greater than 2 times ULN, aminotransferase elevations are greater than 8 times ULN, or aminotransferase elevations persist beyond 2 weeks.', 'Synergism', 'The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133087/', '', 'Gemfibrozil, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Ezetimibe, Bempedoic acid, Colesevelam, Alirocumab, More', 'Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Aminosalicylic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132931, 'Benznidazole', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133088/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More', 'Miltefosine, Pentamidine, Nifurtimox', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132932, 'Berotralstat', 'Lovastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', 'DDInter', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133089/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Ezetimibe, Niacin, Colesevelam, Fluvastatin, More', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132933, 'Boceprevir', 'Lovastatin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 including boceprevir may significantly increase the plasma concentrations of certain HMG-CoA reductase inhibitors and their pharmacologically active metabolites that are primarily metabolized by the isoenzyme. The interaction has been reported in patients receiving lovastatin or simvastatin with other potent CYP450 3A4 inhibitors such as azole antifungal agents, macrolide antibiotics, HIV protease inhibitors, and nefazodone. Clinically, high levels of HMG-CoA reductase inhibitory activity in plasma may be associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.', 'DDInter', 'Due to the potential for severe interaction, concomitant use of lovastatin or simvastatin with boceprevir is considered contraindicated. Red yeast rice, which contains lovastatin, should also be avoided during treatment with boceprevir. Fluvastatin, pravastatin, and pitavastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Due to the potential for severe interaction, concomitant use of lovastatin or simvastatin with boceprevir is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133090/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Ezetimibe, Niacin, Colesevelam, Fluvastatin, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132934, 'Cerivastatin', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133091/', '', 'Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cerivastatin, Colesevelam, Alirocumab, Indapamide, Perindopril, Ramipril, Valsartan', 'Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Lovastatin, Colestipol, Colesevelam, Alirocumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132935, 'Clofibrate', 'Lovastatin', 'Major', 'Severe myopathy and rhabdomyolysis have been reported during concomitant use of HMG-CoA reductase inhibitors and fibric acid derivatives, especially gemfibrozil. Gemfibrozil has been reported to significantly increase the plasma concentrations of some HMG-CoA reductase inhibitors and/or their active metabolites, including lovastatin, simvastatin, pravastatin, cerivastatin, and rosuvastatin (but not fluvastatin). High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity.', 'DDInter', 'Concurrent use of fibric acid derivatives and HMG-CoA reductase inhibitors should generally be avoided unless the benefit of further alterations in lipid levels is anticipated to outweigh the potential risks. Addition of fibrates to HMG-CoA reductase inhibitor therapy typically provides little additional reduction in LDL cholesterol, but further reductions of triglycerides and increases in HDL cholesterol may be attained. Lovastatin labeling recommends that the dosage not exceed 20 mg daily when prescribed with gemfibrozil or other fibrates. All patients treated with HMG-CoA reductase inhibitors and/or fibrates should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. In addition, patients should be closely monitored for hepatotoxicity.', 'Others', 'Concurrent use of fibric acid derivatives and HMG-CoA reductase inhibitors should generally be avoided unless the benefit of further alterations in lipid levels is anticipated to outweigh the potential risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133092/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Clofibrate, Colestipol, Niacin, More', 'Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Lovastatin, Colestipol, Colesevelam, Alirocumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132936, 'Clotrimazole', 'Lovastatin', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors that are substrates of the isoenzyme. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death. The interaction has not been studied with clotrimazole troches or miconazole buccal tablets. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 such as lovastatin, simvastatin, and atorvastatin cannot be ruled out.', 'DDInter', 'Given the potential for serious and life-threatening musculoskeletal toxicity associated with increased plasma levels of HMG-CoA reductase inhibitors, the concomitant use of lovastatin, red yeast rice (which contains lovastatin), and simvastatin with clotrimazole or miconazole mucous membrane preparations should be avoided if possible. Atorvastatin may be used with caution, although the dosage should start low and probably not exceed 40 mg/day. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. No interaction is expected with fluvastatin and pravastatin, since they are not metabolized by CYP450 3A4.', 'Metabolism', 'Given the potential for serious and life-threatening musculoskeletal toxicity associated with increased plasma levels of HMG-CoA reductase inhibitors, the concomitant use of lovastatin, red yeast rice (which contains lovastatin), and simvastatin with clotrimazole or miconazole mucous membrane preparations should be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133093/', '', 'Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, More', 'Salicylic acid, Selenium Sulfide, Thiabendazole, Ciclopirox, Griseofulvin, Econazole, Flucytosine, Tioconazole, Chlorphenesin, Minocycline, Amphotericin B, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132937, 'Dapsone', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133094/', '', 'Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Lomitapide, Niacin, More', 'Minocycline, Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Methylprednisolone, Azelaic acid, Adapalene, Clofazimine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132938, 'Dicoumarol', 'Lovastatin', 'Moderate', 'Lovastatin may enhance the hypoprothrombinemic effects of warfarin. Clinically significant alterations in anticoagulation have been reported. The mechanism is unknown.', 'DDInter', 'Caution is recommended if any HMG-CoA reductase inhibitor is used concomitantly with any oral anticoagulant. Close clinical and laboratory monitoring for altered anticoagulant effect is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is recommended if any HMG-CoA reductase inhibitor is used concomitantly with any oral anticoagulant.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133095/', '', 'Mipomersen, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cerivastatin, Lomitapide, Niacin, Bempedoic acid, Alirocumab, Amlodipine, More', 'Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132939, 'Echinacea', 'Lovastatin', 'Moderate', 'Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.', 'DDInter', 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.', 'Metabolism', 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133096/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Ezetimibe, Niacin, Colesevelam, Gemfibrozil, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132940, 'Elotuzumab', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133097/', '', 'Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132941, 'Entrectinib', 'Lovastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', 'DDInter', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133098/', '', 'Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Bempedoic acid, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Fenofibrate, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132942, 'Enzalutamide', 'Lovastatin', 'Moderate', 'Coadministration with enzalutamide may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-glycoprotein (P-gp) efflux transporter. The proposed mechanism involves accelerated clearance via these routes due to enzalutamide-mediated induction. The resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes.', 'DDInter', 'Caution is advised when enzalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever enzalutamide is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when enzalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-gp, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133099/', '', 'Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More', 'Fulvestrant, Toremifene, Abarelix, Flutamide, Relugolix, Degarelix, Nilutamide, Aminoglutethimide, Abiraterone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132943, 'Erdafitinib', 'Lovastatin', 'Moderate', 'Coadministration with erdafitinib may alter the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme, resulting in increased toxicity or decreased efficacy of these drugs.', 'DDInter', 'Concomitant use of erdafitinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133100/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132944, 'Eribulin', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133101/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Mitotane, Niraparib, Porfimer sodium, Aflibercept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132945, 'Etanercept', 'Lovastatin', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133102/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132946, 'Ethambutol', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133103/', '', 'Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Fenofibrate, More', 'Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Aminosalicylic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132947, 'Ethionamide', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133104/', '', 'Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More', 'Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Aminosalicylic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132948, 'Etoposide', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133105/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Lomitapide, More', 'Topotecan, Irinotecan', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132949, 'Etravirine', 'Lovastatin', 'Moderate', 'Coadministration with etravirine may decrease the plasma concentrations of HMG-CoA reductase inhibitors that are primarily metabolized by CYP450 3A4. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by etravirine.', 'DDInter', 'Pharmacologic response to certain HMG-CoA reductase inhibitors such as atorvastatin, lovastatin, simvastatin, and red yeast rice (which contains lovastatin) should be monitored more closely whenever etravirine is added to or withdrawn from therapy, and the dosage adjusted as necessary.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133106/', '', 'Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Lomitapide, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132950, 'Exenatide', 'Lovastatin', 'Minor', 'Coadministration with exenatide may decrease the plasma concentrations of lovastatin. The mechanism of interaction has not been described. In 30-week controlled clinical trials of exenatide, the use of exenatide in patients receiving HMG-CoA reductase inhibitors was not associated with consistent changes in lipid profiles compared to baseline.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133107/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Lomitapide, Ezetimibe, More', 'Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Tolbutamide, Miglitol, Albiglutide, Ertugliflozin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132951, 'Fedratinib', 'Lovastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', 'DDInter', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133108/', '', 'Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Rosuvastatin, Clofibrate, Colestipol, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132952, 'Fenofibric acid', 'Lovastatin', 'Major', 'Data from observational studies suggest that the risk of severe myopathy and rhabdomyolysis is increased when fibric acid derivatives are coadministered with an HMG-CoA reductase inhibitor (i.e., statin), even in the absence of a marked pharmacokinetic interaction. Additive pharmacodynamic effects may be involved, since these agents individually have been associated with the development of myopathy. Although gemfibrozil has been implicated most often, presumably due to a pharmacokinetic interaction with statins that significantly increases their concentrations in plasma, other fibrates have also been involved.', 'DDInter', 'Caution is advised if delayed-release fenofibric acid is coadministered with a statin. A lower dosage of the statin may be appropriate, particularly if the patient is already receiving the maximum dosage. Coadministration with the maximum dosage of a statin has not been evaluated in clinical studies and should be avoided unless the benefits are expected to outweigh the risks. All patients treated with HMG-CoA reductase inhibitors and/or fibrates should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. In addition, patients should be closely monitored for hepatotoxicity.', 'Others', 'Caution is advised if delayed-release fenofibric acid is coadministered with a statin.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133109/', '', 'Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Ezetimibe, Clofibrate, Niacin, Fenofibrate, Bempedoic acid, More', 'Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Lovastatin, Colestipol, Colesevelam, Alirocumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132953, 'Fluconazole', 'Lovastatin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors (statins) that are substrates of the isoenzyme. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.', 'DDInter', 'The benefits of using azole antifungal agents with statins that are substrates of CYP450 3A4 should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. If coadministration is required, a lower initial and maintenance dosage of the statin should be considered. Close monitoring for musculoskeletal toxicity is recommended, particularly during the initial months of therapy and following a dosage increase of either drug. Pitavastatin, pravastatin, and rosuvastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. Fluvastatin may also be used with azole antifungal agents except fluconazole and voriconazole, both of which can inhibit fluvastatin metabolism via CYP450 2C9. Alternatively, an interruption of the statin may be considered during treatment with an azole antifungal agent. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'The benefits of using azole antifungal agents with statins that are substrates of CYP450 3A4 should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133110/', '', 'Amikacin, Norfloxacin, Levofloxacin, Cefixime, Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin, Salicylic acid, More', 'Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, Alirocumab, Bempedoic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132954, 'Fludarabine', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133111/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Lomitapide, More', 'Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Trifluridine, Floxuridine, Gemcitabine, Pralatrexate, Cytarabine, Decitabine, Azacitidine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132955, 'Fluvastatin', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133112/', '', 'Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Colesevelam, Alirocumab, Fluvastatin, Perindopril, Indapamide', 'Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Lovastatin, Colestipol, Colesevelam, Alirocumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132956, 'Fluvoxamine', 'Lovastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', 'DDInter', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133113/', '', 'Phenelzine, Desipramine, Tranylcypromine, Vilazodone, Trimipramine, Desvenlafaxine, Maprotiline, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, More', 'Gemfibrozil, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Rosuvastatin, Clofibrate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132957, 'Fosamprenavir', 'Lovastatin', 'Major', 'Protease inhibitors (PIs) may significantly increase the plasma concentrations of certain HMG-CoA reductase inhibitors. The mechanism is PI inhibition of CYP450 3A4 metabolism.High levels of HMG-CoA reductase inhibitory activity in plasma are associated with an increased risk of musculoskeletal toxicity, including myopathy and rhabdomyolysis, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.', 'DDInter', 'Simvastatin or lovastatin are considered contraindicated in patients treated with fosamprenavir due to the potential for severe interaction. Red yeast rice (which contains lovastatin) should also be avoided in patients treated with PIs. Fluvastatin and pravastatin are probably safer alternatives, since they are not metabolized by CYP450 3A4. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Simvastatin or lovastatin are considered contraindicated in patients treated with fosamprenavir due to the potential for severe interaction.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133114/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Rosuvastatin, Clofibrate, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132958, 'Fosaprepitant', 'Lovastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', 'DDInter', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133115/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Ezetimibe, Niacin, Colesevelam, Gemfibrozil, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132959, 'Fostamatinib', 'Lovastatin', 'Moderate', 'Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.', 'DDInter', 'Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133116/', '', 'Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More', 'Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132960, 'Fostemsavir', 'Lovastatin', 'Moderate', 'Coadministration with fostemsavir may increase the plasma concentrations of most HMG-CoA reductase inhibitors (i.e., statins) to varying degrees. The proposed mechanism is inhibition of organic anion transporting polypeptide (OATP) 1B1/1B3-mediated hepatic uptake by temsavir, the active moiety of fostemsavir. Inhibition of breast cancer resistance protein (BCRP)-mediated intestinal and hepatic transport of statins may also contribute.', 'DDInter', 'The lowest effective dosage of a statin should be used when prescribed with fostemsavir, and the dosage titrated cautiously based on clinical response and adverse events. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by fever, malaise, and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'The lowest effective dosage of a statin should be used when prescribed with fostemsavir, and the dosage titrated cautiously based on clinical response and adverse events.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133117/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Lomitapide, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132961, 'Gemfibrozil', 'Lovastatin', 'Major', 'Coadministration with gemfibrozil has been shown to significantly increase the plasma concentrations of lovastatin acid, the active metabolite of lovastatin. The mechanism of interaction has not been described.', 'DDInter', 'The use of lovastatin with gemfibrozil or other fibrates should generally be avoided. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark-colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Others', 'The use of lovastatin with gemfibrozil or other fibrates should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133118/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Clofibrate, Lomitapide, Bempedoic acid, Alirocumab, More', 'Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Lovastatin, Colestipol, Colesevelam, Alirocumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132962, 'Sodium aurothiomalate', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133119/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More', 'Penicillamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132963, 'Goldenseal', 'Lovastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', 'DDInter', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133120/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Ezetimibe, Niacin, Colesevelam, Fluvastatin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132964, 'Golimumab', 'Lovastatin', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133121/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132965, 'Grepafloxacin', 'Lovastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', 'DDInter', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133122/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Cerivastatin, Ezetimibe, Niacin, Colesevelam, Fluvastatin, More', 'Enoxacin, Levofloxacin, Norfloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132966, 'Guselkumab', 'Lovastatin', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133123/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132967, 'Hydroxychloroquine', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133124/', '', 'Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Lomitapide, Colestipol, Bempedoic acid, Colesevelam, More', 'Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132968, 'Idarubicin', 'Lovastatin', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.', 'DDInter', 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.', 'Absorption', 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133125/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Ezetimibe, Niacin, Colesevelam, More', 'Valrubicin, Plicamycin, Bleomycin, Mitomycin, Dactinomycin, Epirubicin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132969, 'Idelalisib', 'Lovastatin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of simvastatin and lovastatin and their active acid metabolites, all of which are primarily metabolized by the isoenzyme.', 'DDInter', 'Due to the potential for severe interaction, concomitant use of simvastatin or lovastatin with potent CYP450 3A4 inhibitors is considered contraindicated. Red yeast rice, which contains lovastatin, should also be avoided. Fluvastatin, pravastatin, pitavastatin, and rosuvastatin are probably safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Due to the potential for severe interaction, concomitant use of simvastatin or lovastatin with potent CYP450 3A4 inhibitors is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133126/', '', 'Gemfibrozil, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Ezetimibe, Bempedoic acid, Colesevelam, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132970, 'Imatinib', 'Lovastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', 'DDInter', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133127/', '', 'Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132971, 'Indinavir', 'Lovastatin', 'Major', 'Protease inhibitors (PIs) may significantly increase the plasma concentrations of certain HMG-CoA reductase inhibitors. The mechanism is PI inhibition of CYP450 3A4 metabolism. High levels of HMG-CoA reductase inhibitory activity in plasma are associated with an increased risk of musculoskeletal toxicity, including myopathy and rhabdomyolysis, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.', 'DDInter', 'Simvastatin and lovastatin are considered contraindicated in patients treated with indinavir due to the potential for severe interaction. Red yeast rice (which contains lovastatin) should also be avoided in patients treated with PIs. Fluvastatin and pravastatin are probably safer alternatives, since they are not metabolized by CYP450 3A4. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Simvastatin and lovastatin are considered contraindicated in patients treated with indinavir due to the potential for severe interaction.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133128/', '', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, Famciclovir, More', 'Gemfibrozil, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132972, 'Infliximab', 'Lovastatin', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133129/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 'Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132973, 'Interferon alfa-2a, Recombinant', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133130/', '', 'Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132974, 'Interferon alfa-n1', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133131/', '', 'Oprelvekin, Sipuleucel-T, Elapegademase, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Ezetimibe, Clofibrate, Cerivastatin, Colestipol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132975, 'Interferon alfacon-1', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133132/', '', 'Oprelvekin, Sipuleucel-T, Elapegademase, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132976, 'Diiodohydroxyquinoline', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133133/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Trichlormethiazide, Ciclopirox, Vemurafenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132977, 'Isoniazid', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133134/', '', 'Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Fenofibrate, More', 'Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Cycloserine, Rifabutin, Pyridoxine, Pretomanid, Aminosalicylic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132978, 'Lovastatin', 'Lomitapide', 'Major', 'Coadministration of lomitapide with other agents known to induce hepatotoxicity such as statins may potentiate the risk of liver injury. Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with lomitapide, although the long-term consequences are unknown. Coadministration with lomitapide may increase the plasma concentrations of simvastatin and lovastatin as well as their pharmacologically active acid metabolites. The proposed mechanism is lomitapide inhibition of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of simvastatin and lovastatin and their metabolites.', 'DDInter', 'Simvastatin dosage should be reduced by 50% when initiating therapy with lomitapide. While taking lomitapide, the dosage of simvastatin should be limited to 20 mg daily, or 40 mg daily for patients who have previously tolerated simvastatin 80 mg daily for at least one year without evidence of muscle toxicity. The same precaution with respect to dosage reduction may be applicable to lovastatin or red yeast rice (which contains lovastatin), although clinical data are lacking. Alternatively, fluvastatin, pitavastatin, pravastatin, or rosuvastatin may be given without dosage adjustment in patients receiving lomitapide, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.', 'Metabolism', 'Simvastatin dosage should be reduced by 50% when initiating therapy with lomitapide.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133135/', '', 'Gemfibrozil, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Clofibrate, Lomitapide, Bempedoic acid, Alirocumab, Acetylsalicylic acid, Bempedoic acid, More', 'Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Lovastatin, Colestipol, Colesevelam, Alirocumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132979, 'Lovastatin', 'Lonafarnib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 including lonafarnib may significantly increase the plasma concentrations of certain HMG-CoA reductase inhibitors and their pharmacologically active metabolites that are primarily metabolized by the isoenzyme. Lonafarnib is a potent CYP450 3A time-dependent and mechanism-based inhibitor in vitro. Clinically, high levels of HMG-CoA reductase inhibitory activity in plasma may be associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.', 'DDInter', 'Due to the potential for severe interaction, concomitant use of atorvastatin, lovastatin, or simvastatin with lonafarnib is considered contraindicated. Red yeast rice, which contains lovastatin, should also be avoided during treatment with lonafarnib. Fluvastatin, pravastatin, and pitavastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Due to the potential for severe interaction, concomitant use of atorvastatin, lovastatin, or simvastatin with lonafarnib is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133136/', '', 'Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Rosuvastatin, Clofibrate, Colestipol, More', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132980, 'Lusutrombopag', 'Lovastatin', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of lusutrombopag, which is a substrate of both efflux transporter proteins.', 'DDInter', 'Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors. Pharmacologic response to lusutrombopag should be monitored more closely following initiation, discontinuation, or change of dosage of the concomitant P-gp or BCRP inhibitor.', 'Distribution', 'Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133137/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Cerivastatin, Ezetimibe, Niacin, Atorvastatin, More', 'Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132981, 'Miconazole', 'Lovastatin', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors that are substrates of the isoenzyme. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death. The interaction has not been studied with clotrimazole troches or miconazole buccal tablets. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 such as lovastatin, simvastatin, and atorvastatin cannot be ruled out.', 'DDInter', 'Given the potential for serious and life-threatening musculoskeletal toxicity associated with increased plasma levels of HMG-CoA reductase inhibitors, the concomitant use of lovastatin, red yeast rice (which contains lovastatin), and simvastatin with clotrimazole or miconazole mucous membrane preparations should be avoided if possible. Atorvastatin may be used with caution, although the dosage should start low and probably not exceed 40 mg/day. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. No interaction is expected with fluvastatin and pravastatin, since they are not metabolized by CYP450 3A4.', 'Metabolism', 'Given the potential for serious and life-threatening musculoskeletal toxicity associated with increased plasma levels of HMG-CoA reductase inhibitors, the concomitant use of lovastatin, red yeast rice (which contains lovastatin), and simvastatin with clotrimazole or miconazole mucous membrane preparations should be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133138/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Rosuvastatin, Clofibrate, More', 'Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132982, 'Midostaurin', 'Lovastatin', 'Moderate', 'Coadministration with midostaurin may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and/or organic anion transporting polypeptide (OATP) 1B1 transporters. The proposed mechanism, based on in vitro data, is decreased clearance due to midostaurin-mediated inhibition of P-gp, BCRP, and/or OATP1B1 transport proteins.', 'DDInter', 'Caution is advised if midostaurin is used concomitantly with drugs that are substrates of P-gp, BCRP, and/or OATP1B1 transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever midostaurin is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Caution is advised if midostaurin is used concomitantly with drugs that are substrates of P-gp, BCRP, and/or OATP1B1 transport proteins, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133139/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Fenofibrate, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132983, 'Mifepristone', 'Lovastatin', 'Major', 'Coadministration with mifepristone may significantly increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by mifepristone.', 'DDInter', 'When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing''s syndrome, concomitant use of CYP450 3A4 substrates with narrow therapeutic ranges and high first-pass effect is considered contraindicated. These drugs include lovastatin, simvastatin, cyclosporine, ergot derivatives, fentanyl, oral midazolam, triazolam, pimozide, quinidine, sildenafil, sirolimus, and tacrolimus. The contraindication does not apply when mifepristone is used on a limited basis to terminate a pregnancy, but caution and close monitoring are advisable. Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).', 'Metabolism', 'When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing''s syndrome, concomitant use of CYP450 3A4 substrates with narrow therapeutic ranges and high first-pass effect is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133140/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Ezetimibe, Rosuvastatin, Clofibrate, More', 'Ospemifene, Ulipristal, Prasterone, Bazedoxifene', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132984, 'Mipomersen', 'Lovastatin', 'Major', 'Coadministration of mipomersen with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Mipomersen can cause elevations in serum transaminases and hepatic steatosis.', 'DDInter', 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, lomitapide, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Mipomersen has not been studied with other LDL-lowering agents that can also increase hepatic fat, thus concomitant use is not recommended. Patients treated with mipomersen should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133141/', '', 'Gemfibrozil, Mipomersen, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Ezetimibe, Bempedoic acid, More', 'Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Lovastatin, Colestipol, Colesevelam, Alirocumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132985, 'Naxitamab', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133142/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132986, 'Nefazodone', 'Lovastatin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 such as nefazodone may significantly increase the plasma concentrations of simvastatin and lovastatin and their active acid metabolites, all of which are primarily metabolized by the isoenzyme. Nefazodone has been reported to increase systemic exposure (AUC) to simvastatin and its pharmacologically active acid metabolite by 20-fold. Although not studied, the interaction is also expected to occur with lovastatin due to its similar metabolic profile to simvastatin. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death. There have been case reports of patients treated with simvastatin who developed severe myopathy or rhabdomyolysis during coadministration of nefazodone.', 'DDInter', 'Due to the potential for severe interaction, concomitant use of simvastatin or lovastatin with potent CYP450 3A4 inhibitors such as nefazodone is considered contraindicated. Fluvastatin, pravastatin, pitavastatin, and rosuvastatin are probably safer alternatives, since they are not metabolized by CYP450 3A4, although pravastatin was cited in a case report of suspected interaction that resulted in asymptomatic increases in creatine kinase levels. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Due to the potential for severe interaction, concomitant use of simvastatin or lovastatin with potent CYP450 3A4 inhibitors such as nefazodone is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133143/', '', 'Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, More', 'Phenelzine, Desipramine, Tranylcypromine, Vilazodone, Trimipramine, Desvenlafaxine, Maprotiline, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132987, 'Nelarabine', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133144/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More', 'Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Trifluridine, Floxuridine, Gemcitabine, Pralatrexate, Cytarabine, Decitabine, Azacitidine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132988, 'Nelfinavir', 'Lovastatin', 'Major', 'Protease inhibitors (PIs) may significantly increase the plasma concentrations of certain HMG-CoA reductase inhibitors. The mechanism is PI inhibition of CYP450 3A4 metabolism. High levels of HMG-CoA reductase inhibitory activity in plasma are associated with an increased risk of musculoskeletal toxicity, including myopathy and rhabdomyolysis, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.', 'DDInter', 'Simvastatin and lovastatin are considered contraindicated in patients treated with nelfinavir due to the potential for severe interaction. Red yeast rice (which contains lovastatin) should also be avoided in patients treated with PIs. Fluvastatin and pravastatin are probably safer alternatives, since they are not metabolized by CYP450 3A4. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Simvastatin and lovastatin are considered contraindicated in patients treated with nelfinavir due to the potential for severe interaction.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133145/', '', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, Famciclovir, More', 'Gemfibrozil, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132989, 'Nevirapine', 'Lovastatin', 'Moderate', 'Coadministration with efavirenz may decrease the plasma concentrations and pharmacologic effects of certain HMG-CoA reductase inhibitors (i.e., statins) and/or their active metabolites. The proposed mechanism is efavirenz induction of CYP450 3A4 metabolism. Neither simvastatin, atorvastatin, nor pravastatin had any effect on the pharmacokinetics of efavirenz.', 'DDInter', 'Coadministration of simvastatin, atorvastatin, or other statins that are primarily metabolized by CYP450 3A4 (e.g., lovastatin) with efavirenz may result in diminished hypolipidemic efficacy. Although pravastatin is not significantly metabolized by CYP450 3A4, it has also been implicated. Dosage adjustment of these statins may be necessary if they are prescribed with efavirenz. The same precaution may be applicable during therapy with nevirapine, another nonnucleoside reverse transcriptase inhibitor that induces CYP450 3A4.', 'Metabolism', 'Coadministration of simvastatin, atorvastatin, or other statins that are primarily metabolized by CYP450 3A4 (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133146/', '', 'Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Rilpivirine, Dolutegravir, Brincidofovir, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132990, 'Nilotinib', 'Lovastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', 'DDInter', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133147/', '', 'Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Ezetimibe, Rosuvastatin, Clofibrate, Colestipol, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132991, 'Nitrofurantoin', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133148/', '', 'Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, More', 'Bacitracin, Oritavancin, Polymyxin B, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132992, 'Olaparib', 'Lovastatin', 'Moderate', 'Based on in vitro inhibition data, coadministration with olaparib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 (e.g., cisapride, ergot alkaloids, fentanyl, lovastatin, oral midazolam, pimozide, quetiapine, simvastatin, triazolam, vinca alkaloids), P-gp (e.g., colchicine, dabigatran, digoxin), breast cancer resistance protein (BCRP) (e.g., rosuvastatin), OATP1B1 (e.g., eluxadoline, glyburide, repaglinide, statins, valsartan), or organic cation transporter 1 or 2 (OCT1, OCT2) (e.g., metformin). The proposed mechanism is decreased clearance due to inhibition of the corresponding metabolizing enzyme and/or efflux/uptake transporter by olaparib.', 'DDInter', 'Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever olaparib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133149/', '', 'Cholestyramine, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Cerivastatin, Ezetimibe, Niacin, Atorvastatin, Colesevelam, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Mitotane, Niraparib, Porfimer sodium, Aflibercept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132993, 'Osilodrostat', 'Lovastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', 'DDInter', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133150/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Ezetimibe, Niacin, Colesevelam, Fluvastatin, Gemfibrozil, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132994, 'Osimertinib', 'Lovastatin', 'Moderate', 'Coadministration with osimertinib may alter the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. In vitro, osimertinib has been shown to be a competitive inhibitor as well as inducer of CYP450 3A4.', 'DDInter', 'Concomitant use of osimertinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.', 'Metabolism', 'Concomitant use of osimertinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133151/', '', 'Cholestyramine, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Cerivastatin, Ezetimibe, Niacin, Atorvastatin, Colesevelam, Fluvastatin, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132995, 'Oxaliplatin', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133152/', '', 'Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, Alirocumab, Bempedoic acid', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Mitotane, Niraparib, Porfimer sodium, Aflibercept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132996, 'Oxcarbazepine', 'Lovastatin', 'Moderate', 'Coadministration with oxcarbazepine may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by oxcarbazepine.', 'DDInter', 'Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oxcarbazepine is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133153/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Lomitapide, More', 'Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Rufinamide, Paramethadione, Perampanel, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132997, 'Paclitaxel (protein-bound)', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133154/', '', 'Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132998, 'Palbociclib', 'Lovastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', 'DDInter', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133155/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Ezetimibe, Niacin, Colesevelam, Fluvastatin, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (132999, 'Pantoprazole', 'Lovastatin', 'Moderate', 'A case report suggests that coadministration with esomeprazole may increase the plasma concentrations of atorvastatin and the associated risk of myopathy. The proposed mechanism is competitive inhibition of intestinal P-glycoprotein, resulting in decreased drug secretion into the intestinal lumen and increased drug bioavailability. Another, perhaps minor mechanism is competitive inhibition of CYP450 3A4 metabolism.', 'DDInter', 'Because of the increased risk of musculoskeletal toxicity associated with high levels of HMG-CoA reductase inhibitory activity in plasma, patients treated with atorvastatin, lovastatin, simvastatin, and red yeast rice (which contains lovastatin) should be monitored more closely during concomitant use of proton pump inhibitors. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report to their physician any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated or if myopathy is suspected or diagnosed.', 'Metabolism, Absorption', 'Because of the increased risk of musculoskeletal toxicity associated with high levels of HMG-CoA reductase inhibitory activity in plasma, patients treated with atorvastatin, lovastatin, simvastatin, and red yeast rice (which contains lovastatin) should be monitored more closely during concomitant use of proton pump inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133156/', '', 'Levofloxacin, Bismuth subcitrate potassium, Dexlansoprazole, Rifabutin', 'Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Lomitapide, Colestipol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (133000, 'Pazopanib', 'Lovastatin', 'Moderate', 'Concomitant use of pazopanib with simvastatin may increase the risk of ALT elevations, possibly due to additive hepatotoxic effects.', 'DDInter', 'Caution is advised if pazopanib is used in combination with simvastatin. Serum liver transaminases and bilirubin should be measured prior to initiation of pazopanib and regularly during treatment as recommended in the product labeling. If ALT elevations occur, simvastatin should be discontinued and guidelines for pazopanib dosage adjustments should be followed, or alternatives to pazopanib considered. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, light colored stools, and jaundice. Insufficient data are available to assess the risk of pazopanib administered concomitantly with other HMG-CoA reductase inhibitors.', 'Synergism', 'Caution is advised if pazopanib is used in combination with simvastatin.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/133157/', '', 'Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, Fenofibrate, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More', 1767369485);
